Trial · NCT02265952
Outcomes22
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 22
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| SECONDARY | Absolute Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline (Week 0) to Week 4 in the Main Study Period | Baseline (Week 0) up to Week 4 | mg/dL | MEAN | |
| PRIMARY | Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline (Week 0) to Week 4 in the Main Study Period | Baseline (Week 0) up to Week 4 | Percent Change | MEAN | |
| SECONDARY | Absolute Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Week 2 to Week 4 in the Main Study Period | Week 2 to Week 4 | Milligram per Deciliter (mg/dL) | MEAN | |
| SECONDARY | Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Week 2 to Week 4 in the Main Study Period | Week 2 to Week 4 | Percent Change | MEAN | |
| SECONDARY | Absolute Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline (Week 0) Over Time in the Main Study Period | Baseline (Week 0) up to Week 26 | n = Number of participants who were evaluable for this endpoint at a given time point. | mg/dL | MEAN |
| SECONDARY | Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline (Week 0) Over Time in the Main Study Period | Baseline (Week 0) up to Week 26 | n = Number of participants who were evaluable for this endpoint at a given time point. | Percent Change | MEAN |
| SECONDARY | Absolute Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline (Week 26) to Week 214 in the Open Label Extension (OLE) Period | Baseline (Week 26) up to Week 214 | n = Number of participants who were evaluable for this endpoint at a given time point. | mg/dL | MEAN |
| SECONDARY | Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline (Week 26) to Week 214 in the Open Label Extension (OLE) Period | Baseline (Week 26) up to Week 214 | n = Number of participants who were evaluable for this endpoint at a given time point. | Percent Change | MEAN |
| SECONDARY | Absolute Change in Apolipoprotein (Apo B), Non-High-Density Lipoprotein Cholesterol (Non-HDL-C), Total Cholesterol (Total-C), and Lipoprotein(a) (Lp[a]) From Baseline (Week 0) up to Week 26 in the Main Study Period | Baseline (Week 0) up to Week 26 | n = Number of participants who were evaluable for this endpoint at a given time point. | mg/dL | MEAN |
| SECONDARY | Percent Change in Apolipoprotein (Apo B), Non-High-Density Lipoprotein Cholesterol (Non-HDL-C), Total Cholesterol (Total-C), and Lipoprotein(a) (Lp[a]) From Baseline (Week 0) up to Week 26 in the Main Study Period | Baseline (Week 0) up to Week 26 | n = Number of participants who were evaluable for this endpoint at a given time point. | Percent Change | MEAN |
| SECONDARY | Absolute Change in Apolipoprotein (Apo B), Non-High-Density Lipoprotein Cholesterol (Non-HDL-C), Total Cholesterol (Total-C), and Lipoprotein(a) (Lp[a]) From Baseline (Week 26) to Week 214 in the Open Label Extension (OLE) Period | Baseline (Week 26) up to Week 214 | n = Number of participants who were evaluable for this endpoint at a given time point. | mg/dL | MEAN |
| SECONDARY | Percent Change in Apolipoprotein (Apo B), Non-High-Density Lipoprotein Cholesterol (Non-HDL-C), Total Cholesterol (Total-C), and Lipoprotein(a) (Lp[a]) From Baseline (Week 26) to Week 214 in the Open Label Extension (OLE) Period | Baseline (Week 26) up to Week 214 | n = Number of participants who were evaluable for this endpoint at a given time point. | Percent change | MEAN |
| SECONDARY | Percentage of Participants Who Achieved Reduction in Low-Density Lipoprotein Cholesterol (LDL-C) of ≥ 25% From Baseline (Week 0) in the Main Study Period | Baseline (Week 0) up to Week 26 | Percentage of participants | NUMBER | |
| SECONDARY | Percentage of Participants Who Achieved Reduction in Low-Density Lipoprotein Cholesterol (LDL-C) of ≥ 25% From Baseline (Week 26) in the Open Label Extension (OLE) Period | Baseline (Week 26) to Week 214 | Percentage of participants | NUMBER | |
| SECONDARY | Percentage of Participants Who Achieved Reduction in Low-Density Lipoprotein Cholesterol (LDL-C) of ≥ 50% From Baseline (Week 0) in the Main Study Period | Baseline (Week 0) to Week 26 | Percentage of participants | NUMBER | |
| SECONDARY | Percentage of Participants Who Achieved Reduction in Low-Density Lipoprotein Cholesterol (LDL-C) of ≥ 50% From Baseline (Week 26) in the Open Label Extension (OLE) Period | Baseline (Week 26) up to Week 214 | Percentage | NUMBER | |
| SECONDARY | Absolute Change in High-Density Lipoprotein Cholesterol (HDL-C), Triglycerides (TG), and Apolipoprotein A-1 (Apo A-1) From Baseline (Week 0) Over Time in the Main Study Period | Baseline (Week 0) up to Week 26 | n = Number of participants who were evaluable for this endpoint at a given time point. | mg/dL | MEAN |
| SECONDARY | Percent Change in High-Density Lipoprotein Cholesterol (HDL-C), Triglycerides (TG), and Apolipoprotein A-1 (Apo A-1) From Baseline (Week 0) Over Time in the Main Study Period | Baseline (Week 0) up to Week 26 | n = Number of participants who were evaluable for this endpoint at a given time point. | Percent Change | MEAN |
| SECONDARY | Percent Change in High-Density Lipoprotein Cholesterol (HDL-C), Triglycerides (TG), and Apolipoprotein A-1 (Apo A-1) From Baseline (Week 26) to Week 214 in the Open Label Extension (OLE) Period | Baseline (Week 26) up to Week 214 | n = Number of participants who were evaluable for this endpoint at a given time point. | Percent change | MEAN |
| SECONDARY | Absolute Change in High-Density Lipoprotein Cholesterol (HDL-C), Triglycerides (TG), and Apolipoprotein A-1 (Apo A-1) From Baseline (Week 26) to Week 214 in the Open Label Extension (OLE) Period | Baseline (Week 26) up to Week 214 | n = Number of participants who were evaluable for this endpoint at a given time point. | mg/dL | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02265952/outcomes